On April 21, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) reported that the company will provide an update on clinical data from its Phase 1 and 2 studies of GMI-1271 at the 2017 American Society for Clinical Oncology in Chicago (Press release, GlycoMimetics, APR 21, 2017, View Source [SID1234518662]). GMI-1271 is an antagonist of E-selectin, for which prior data has shown an emerging and differentiated efficacy profile. Schedule your 30 min Free 1stOncology Demo! Details of the ASCO (Free ASCO Whitepaper) presentations include:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract #2520
Poster discussion. DeAngelo, D.J., et al. "GMI-1271, a Novel E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML." Session Title: Poster Discussion Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics, Monday, June 5, 11:30 a.m.-12:45 p.m. CT.
Presenter: Daniel J. DeAngelo, MD, PhD, Dana Farber Cancer Institute Director of Clinical and Translational Research, Adult Leukemia, and Institute Physician ; Harvard Medical School Associate Professor of Medicine
Abstract #2560
Poster. DeAngelo, D.J. et al. "GMI-1271, a Novel E-Selectin Antagonist, Combined with Induction Chemotherapy in Elderly Patients with Untreated AML." Session Title: Poster Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics. Monday, June 5, 8:00-11:30 a.m. CT.
Presenter: Dr. DeAngelo
The ASCO (Free ASCO Whitepaper) Annual Meeting 2017 takes place from June 2 to 5, at McCormick Place in Chicago. Meeting abstracts are available at ASCO (Free ASCO Whitepaper)’s website.